The First Drugs Designed to Fight Aging Are Ready for Human Testing
September 6, 2017
(Quartz) – Earlier this week, doctors at the Mayo Clinic and the Scripps Research Institute published a review article in the Journal of American Geriatrics calling and outlining designs for human clinical trials on the first class of drugs developed specifically to treat aging. The “geroscience hypothesis” is relatively new to the world of accepted science. It states that targeting the fundamental mechanisms of aging can help treat or delay the onset of age-related diseases like type 2 diabetes, osteoporosis, and various forms of cancers. The idea is to increase healthspan: the years in which people are viable, active members of society. The subtext though, is that these treatments also have the potential to delay aging itself.